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The Monographs produced by the International Agency for Research on Cancer (IARC) apply 
rigorous procedures for the scientific review and evaluation of carcinogenic hazards by 
independent experts. The Preamble to the IARC Monographs, which outlines these procedures, 
was updated in 2019, following recommendations of a 2018 expert Advisory Group. This article 
presents the key features of the updated Preamble, a major milestone that will enable IARC to 
take advantage of recent scientific and procedural advances made during the 12 years since the 
last Preamble amendments. The updated Preamble formalizes important developments already 
being pioneered in the Monographs Programme. These developments were taken forward in a 
clarified and strengthened process for identifying, reviewing, evaluating and integrating evidence 
to identify causes of human cancer. The advancements adopted include strengthening of 
systematic review methodologies; greater emphasis on mechanistic evidence, based on key 
characteristics of carcinogens; greater consideration of quality and informativeness in the critical 
evaluation of epidemiological studies, including their exposure assessment methods; improved 
harmonization of evaluation criteria for the different evidence streams; and a single-step process 
of integrating evidence on cancer in humans, cancer in experimental animals and mechanisms for 
reaching overall evaluations. In all, the updated Preamble underpins a stronger and more 












For nearly 50 years, the Monographs Programme of the International Agency for 
Research on Cancer (IARC) has been a premier global resource for identifying agents that can 
cause cancer. The identification of carcinogenic hazards is a necessary initial step in cancer 
prevention. National and international authorities and organizations use information on causes of 
cancer to support actions to reduce human exposure to carcinogens.  
More than 1000 agents have been evaluated in the Monographs Programme. These 
evaluations have addressed chemical, physical, and biological substances, working conditions, 
dietary constituents, and other exposures of everyday life. Slightly more than half of all agents 
evaluated have been classified as possibly carcinogenic, probably carcinogenic or carcinogenic to 
humans (https://Monographs.iarc.fr/agents-classified-by-the-iarc/). 
 The IARC Monographs embody principles of scientific rigour, impartial evaluation, 
transparency, and consistency. Long-standing hallmarks of Monographs evaluations include the 
transparent synthesis of different streams of evidence and their integration into uniform 
classifications of the strength of evidence for causation12,13,1. Three streams of scientific evidence 
are considered: studies of human cancer, studies of cancer in experimental animals, and 
mechanistic evidence. Human exposure is also characterized. The evaluation process has evolved 
since the Programme’s inception, in 1971, in parallel with the evolution of the scientific evidence 
on causation and experience gained over the decades of the Programme’s existence. Starting in 
1982, it has been possible to “upgrade” overall evaluations based on results from short-term 
genotoxicity assays. In 1991, a Working Group proposed principles and procedures for use of 
mechanistic evidence for overall evaluations, specifying criteria for mechanistic upgrades to a 
higher hazard category, as well as criteria for downgrades to a lower category based on the extent 
of mechanistic understanding. The update of the Preamble2 described here reflects the changing 
mix of scientific evidence considered by Monographs Working Groups, notably the 










mechanistic data include the identification of “key characteristics of carcinogens”, which provide 
a framework for organizing mechanistic data and assessing strengths as well as gaps in evidence4–
7. The revisions to the Preamble reflect these advances and describe a harmonized process for 
integrating evidence from epidemiological studies, experimental animal bioassays, and 
mechanistic data to reach a carcinogenicity classification. 
While IARC Working Groups have always conducted comprehensive reviews of 
evidence of carcinogenicity, advances in systematic review methods8–12 provide a basis for more 
specific guidance to Working Group members, thereby enhancing consistency and transparency. 
IARC has embraced these methods and incorporated them into its procedures for assembling and 
assessing evidence13. Rather than relying on specific checklists and scoring methodologies for 
evaluating studies, the revised Preamble specifies review procedures to formally consider the 
quality of the studies that are tailored to each stream of evidence and the types of studies 
available.  
Given the potential importance and impact of the classification of an agent, consideration 
has long been given to managing conflicts of interest on the part of all participants in a Working 
Group meeting. For enhanced transparency, the 2006 Preamble strengthened conflict of interest 
management and delineated the distinct roles of different participants (Working Group Members, 
Invited Specialists, Representatives, Observers, IARC Secretariat)14,15. The revised Preamble 
maintains a robust process for identifying, evaluating and disclosing conflicts of interest. 
Commitments to transparency are extended, including in the area of engagement with the public 
and in broadening of the admissible data sources, while maintaining the requirement that the 
information used be publicly available. 
This Commentary describes the motivation and methodology for the recent update to the 
Preamble for the Monographs Programme of IARC, and highlights the key changes adopted. In 










are communicated more broadly. The Preamble offers a well-established framework for evidence 
integration and, as such, the new approach to considering mechanistic evidence is of broad 
interest. 
 
Motivation and Process for Preamble Revision 
Since 2006, substantial growth has occurred in the scientific understanding of factors contributing 
to carcinogenicity as well as in the development of methods for information gathering, evidence 
assessment, and integration. In 2018, IARC convened an Advisory Group to Recommend an 
Update to the Preamble, with broad expertise across multiple disciplines to consider scientific 
progress and the views of different stakeholders on these important developments. IARC solicited 
input through a six-month public comment period, during which more than 30 individuals or 
institutions responded (https://Monographs.iarc.fr/wp-
content/uploads/2018/11/Preamble_PublicComments.pdf). In addition, IARC sought expert input 
during a scientific webinar held in advance of the Advisory Group meeting 
(https://Monographs.iarc.fr/wp-content/uploads/2018/11/Webinar-presentations.pdf).  
The Advisory Group comprised 21 members from 9 countries, with a range of expertise 
including exposure characterization, epidemiology, cancer bioassays, carcinogen mechanisms, 
risk assessment, systematic review, and philosophy of science. From 12–14 November 2018, the 
Advisory Group met to finalize recommendations to update the Preamble. Other meeting 
participants included two Invited Specialists, seven Representatives of national and international 
health agencies, three Observers from interested organizations, and 16 members of the 
IARC/WHO Secretariat. The Advisory Group carefully considered written comments from the 
public, scientific webinar presentations, and input from all meeting participants.  
The Advisory Group made specific recommendations for revising the Preamble and 










accepted these recommendations, and authorised the updated Preamble for immediate use in the 
Monographs Programme.  
 
Key changes in the revised Preamble  
General procedures 
The Advisory Group encouraged IARC to clarify the purpose and scope of the Monographs 
evaluations. In this regard, the name of the Monographs series has been changed to the IARC 
Monographs on the Identification of Carcinogenic Hazards to Humans. This change, while 
semantic in nature, reflects the important distinction between hazard and risk: “hazard” refers to 
the strength of the evidence that an agent is a carcinogen, while “risk” refers to the probability 
that a given exposure to a carcinogen will result in cancer. From the onset of the program, the 
Monographs have evaluated the potential cancer hazard of an agent. Hazard identification as 
conducted within the Monographs is distinct from risk assessment, in which exposure-response 
characterization is used to estimate cancer risk for a given scenario and level of exposure.  
The collective application of informed judgment by experts is an integral and critical 
component of the Monograph development process. The updated Preamble, incorporating 
recommendations from the Advisory Group, emphasizes the necessity of relying on international 
experts who are free from conflicts of interest and clearly describes current procedures for 
evaluating conflicts of interest. Such conflicts are largely financial in nature, but public 
statements and positions related to the subject of the meeting are also considered. Furthermore, 
while the use of WHO’s Declaration of Interests to identify conflicting interests is a long-term 
strength of the Programme, the Advisory Group recommended that IARC go further and 
communicate its expectation that Working Group members not use their participation in IARC 










Group should not engage in consulting or other activities involving the agents under review, until 
after publication of the Monograph volume. 
Rationales for IARC practices in convening expert groups were also clarified. For 
example, IARC’s reliance on subject-matter experts who have published studies on the agents 
under review has shown value borne out by decades of experience in the Monographs 
Programme. This experience has shown that the vast majority of Working Group members are 
committed to a fair and objective evaluation of the evidence according to the scientific principles 
and criteria set forth in the Preamble, and not to advancement of their own research findings or 
careers. Nevertheless, the Preamble recommends several steps to minimize the undue influence 
of any such “careerism”, should it occur, on a Monograph evaluation. First, in inviting experts, 
consideration is given to diversity in scientific approaches and views. Second, study summaries 
are drafted or peer reviewed by a Working Group member who is not associated with the study 
and by members of the IARC Secretariat. Third, the identification, screening, organization, and 
data extraction from the literature are standardized and are executed by several individuals, 
including the Secretariat. The peer review explicitly addresses whether inclusion and exclusion, 
data extraction, and summarization of strengths and limitations for each study were carried out in 
an unbiased manner. Fourth, the peer review expands during the meeting to include the subgroup 
evaluating individual evidence streams, e.g., studies of cancer in humans, and then to the entire 
Working Group. Within subgroups, studies are presented for discussion by independent experts 
and undergo scrutiny by the whole subgroup (including experts who have not worked directly 
with the agent). The entire body of evidence is synthesized through discussion first within 
subgroup and then in Plenary sessions. Lastly, to transparently document the process, the 
Working Group is asked to lay out clear reasoning for its decisions, describe the role of expert 










process, the entire volume becomes the collective consensus product of the Working Group and 
the influence of any individual is minimized.   
The revised Preamble also clarifies the responsibilities of the expert Working Groups in 
strengthening the use and documentation of systematic review methodology in the evaluations of 
cancer in humans, cancer in experimental animals, and mechanistic evidence. In particular, the 
Working Group is responsible for assuring that the relevant studies have been identified and 
selected, for assessing the methods and quality of individual studies, and for accurately reporting 
the study characteristics and results. Steps related to systematically searching for evidence, 
screening, data extraction, and study quality evaluation are clearly outlined. 
Considerations of study quality are tailored to each evidence stream. The revised 
Preamble describes in greater detail the thorough peer review undertaken throughout the 
evaluation process, including during identification of relevant information, study review, and data 
extraction, as well as Monograph drafting, revision, and discussion. The Advisory Group 
considered whether the Preamble should discuss the use of specific quality assessment and 
systematic review tools but recognized that these tools are rapidly evolving and are more 
appropriately discussed in the Instruction for Authors (https://monographs.iarc.fr/instructions-for-
authors/) that IARC provides for Working Group members. As the Programme keeps abreast of 
pertinent methodological developments, this allows flexibility for experimentation with new 
procedures, which can then be adopted once empirically demonstrated to improve the validity of 
the carcinogenicity evaluation.  
Scientific Review and Evaluation 
The revised Preamble defines how the principles of systematic review – e.g., formal 
consideration of quality of the studies (e.g., design, methodology), and reporting of results that 
are tailored to each stream of evidence and the types of studies available – apply to IARC 










judgements. At the same time, it is designed to be flexible enough to enable incorporation of 
further scientific advances as these arise. 
Exposure characterization: The revised Preamble retains the primary aims and 
methodology of the exposure characterization section: to identify the agent, to describe its 
occurrence, main uses, and production (when relevant), and to summarize exposure measurement 
methods and the prevalence and concentrations in affected human populations. In relation to its 
enhanced description of these concepts, the revised Preamble re-emphasizes the importance of 
summarizing data on exposure circumstances in low- and middle-income countries whenever 
feasible. A critical review of the strengths and limitations of the exposure assessment methods 
used in key studies of cancer or cancer mechanisms in humans is an important addition to this 
section. This review is integral in considering study quality and informativeness in the 
evaluations of the human cancer and mechanistic evidence.  
Studies of cancer in humans: The revised Preamble maintains and builds on many aspects 
of earlier versions to promote a synthetic review of human cancer studies that focuses on the most 
informative studies, while including a detailed evaluation of their quality. The scope of the review 
and inclusion criteria, consisting of all pertinent epidemiological studies evaluating the 
association between exposure to the agent and human cancer as an outcome, are retained. Greater 
detail is given on the most critical aspects of study quality considered by the Working Group, 
including those related to the study description, study population (including evaluation of 
selection bias), exposure assessment methods, outcome measurement, assessment of the potential 
for and likely impact of confounding, and statistical methods. In addition, the revised Preamble 
adds the explicit consideration of study informativeness (described elsewhere as “study 
sensitivity”17). An informative study is one that is likely to detect a true association. 
Considerations include whether the study population is of sufficient size to obtain precise 










measurement of outcome for an effect to be observable; the presence of adequate exposure 
contrast; the use of biologically relevant definitions of exposure; and the inclusion of relevant and 
well-defined time-windows for exposure and outcome18. The Advisory Group recommended 
against mandating the use of any specific checklists and scoring systems in favor of using 
procedures aligned with the principles outlined in the Preamble that are tailored to the evidence 
reviewed19. While the revised Preamble has been designed to accommodate flexibility as 
evaluation methods evolve, each Monograph Working Group is encouraged to lay out clear 
reasoning for its decisions, describing the basis of expert judgment in those decisions. Further, the 
approach to synthesizing epidemiological evidence for causal inference as applied to cancer 
hazard identification continues to include consideration of the strength, consistency, and 
temporality of the association, assessment of any exposure-response gradients, and evaluation of 
the coherence with physiological and biological knowledge related to exposure to the target tissue 
or organ, latency and timing of exposure. Through this synthetic review process, the Working 
Group characterizes the body of evidence of cancer in humans as showing sufficient, limited, or 
inadequate evidence of carcinogenicity (Table 1), or evidence suggesting lack of carcinogenicity. 
The evidence is evaluated by organ or tissue site.  
Studies of cancer in experimental animals: The revised Preamble retains most aspects of 
the evaluation of studies of cancer in experimental animals. The particular attributes that are 
considered for evaluating quality include agent characterization, dose monitoring, dosing 
regimen, appropriateness of experimental animal model, sample sizes, exposure effects on 
survival and body weight, group allocation and randomization, histopathological review, data 
reporting, and data analysis. For certain exposures (e.g., viruses specific to humans), it is 
emphasised that studies using genetically modified animals may provide particularly important 
experimental evidence. Statistical considerations are described for different test conditions, such 










Guidance is provided on the use of concurrent versus historical control groups. After reviewing 
study quality and findings, a determination is made of whether there is sufficient, limited, or 
inadequate evidence of carcinogenicity (Table 1), or evidence suggesting lack of carcinogenicity. 
It is noteworthy that new criteria have been added for the determination of limited evidence, e.g., 
the agent causes cancer in observational studies in non-laboratory animals, or increases tumour 
multiplicity or decreases tumour latency in experimental animals. 
Studies of carcinogen mechanisms: Both the availability and utility of mechanistic 
evidence to inform the evaluation of carcinogenicity have increased substantially since the 
Preamble was last updated. On the other hand, epidemiological studies of cancer and lifetime 
cancer bioassays in rodents may be available for only a fraction of agents to which humans are 
currently exposed4,20. Several reports from the US National Academies of Sciences, Engineering, 
and Medicine have described how toxicity testing, hazard identification, and risk assessment have 
been or are anticipated to be transformed by mechanistic data10,11,21. Additionally, IARC’s review 
of Group 1 carcinogens22, as well as recent experience of IARC Working Groups, has shown how 
mechanistic data can play a role in evaluations of carcinogenicity4–6. In particular, human 
carcinogens often exhibit one or more key characteristics that are related to how they cause 
cancer, and different carcinogenic agents exhibit different spectra of these key characteristics. 
The key characteristics described by Smith and colleagues5 (see Box 1), such as “is genotoxic”, 
“is immunosuppressive”, or “modulates receptor-mediated effects”, are based on empirical 
observations of the chemical and biological properties associated with the human carcinogens 
identified by the IARC Monographs Programme up to and including Volume 100. Key 
characteristics are distinct from the “hallmarks of cancer”, which relate to the properties of cancer 
cells23,24. Key characteristics are also distinct from hypothesized mechanistic pathways, which 
describe a sequence of biological events postulated to occur during carcinogenesis. As such, the 










narrow focus on specific pathways and hypotheses and provides for a broad, holistic 
consideration of the mechanistic evidence”11.  
Given the increasing emphasis on mechanistic data, the Preamble also recognized the 
importance of evaluating the quality of study design, exposure assessment methods, and biologic 
assay validity and reliability for human studies that evaluate potential mechanisms relevant to 
carcinogenesis. This evaluation is in line with the review of epidemiologic studies of cancer, and 
takes into consideration issues relevant to the assessment of mechanistic endpoints25,26. Similarly, 
quality considerations are emphasized in the review of mechanistic studies conducted in other 
species and experimental systems (e.g., the suitability of the endpoint, the dosing range, and of 
the test article for in vitro studies, as well as completeness of reporting). 
The evidence that the agent exhibits key characteristics of carcinogens is categorized 
according to one of three distinct terms (strong, limited, inadequate), the latter two aligning with 
terms used for the human and animal evidence (Table 1). When the mechanistic evidence is 
strong, further specification (i.e., from exposed humans, human primary cells or tissues, or 
experimental systems) is used to guide the overall evaluation. 
A substantial part of the evaluation of mechanistic evidence is organized around the key 
characteristics of carcinogens as initially identified5. However, it is recognized that the set of key 
characteristics of carcinogens may evolve with additional experience and scientific 
understanding6. This may occur as new carcinogens with new characteristics are identified in the 
future. Progress in understanding the differences in the relative importance among key 
characteristics, and the assays providing evidence of them, is also anticipated6,7,8. As noted in the 
Preamble, some human carcinogens exhibit a single or primary key characteristic, while for 
others, evidence for a group of key characteristics may be needed to strengthen mechanistic 
conclusions. For instance, non-carcinogens can also induce oxidative stress, and the Preamble 










unless found in combination with other key characteristics. Further development and mapping of 
toxicological and biomarker endpoints and pathways relevant to the key characteristics can 
advance understanding of the evidence and assays most informative for carcinogen hazard 
identification6,7.  
In addition, evidence that falls outside of the recognized key characteristics of 
carcinogens, reflecting emerging knowledge or important novel scientific developments on 
carcinogen mechanisms, may also be included. Moreover, the revised Preamble retains the option 
to assess the strength of evidence for mechanistic classes; these considerations can go beyond 
chemical similarity and quantitative structure-activity relationships to include common biological 
activities across dissimilar chemicals. Also retained is consideration of the strength of evidence 
based on authoritative criteria for determining that tumours in experimental animals are induced 
by mechanisms that do not operate in humans. Strong evidence in each of these circumstances 
can be influential in the overall evaluation. 
Overall evaluation: A major revision in the overall evaluation process was to allow for 
mechanistic data to be explicitly considered simultaneously along with evidence from studies of 
cancer in humans and in experimental animals. Previously, integration of mechanistic evidence 
usually occurred after the evaluation of human and experimental animal cancer evidence. In the 
revised Preamble, all three bodies of evidence are considered together, and integrated according 
to the procedure in Table 2.  
Another revision is that the evaluation categories were simplified to encompass one of 
four “Groups” (Group 1, 2A, 2B or 3; see Box 2), rather than five (Group 1, 2A, 2B, 3 or 4), as 
previously. The IARC Monographs Programme selects agents for review only if there is evidence 
of human exposure and some evidence suggesting carcinogenicity. Therefore, the previous Group 
3 (not classifiable) and Group 4 have been combined, and Working Groups are encouraged to 










instance, this statement may be appropriate when multiple well-conducted and highly precise 
epidemiological studies did not find a positive association between the agent and cancer in 
humans. However, a definitive determination of an absence of any carcinogenic hazard to 
humans based on epidemiological studies requires assurances that all susceptible populations, 
exposure circumstances, cancer outcomes, and relevant variables be captured adequately in the 
body of available studies, which in practice is nearly impossible to attain. An evaluation as Group 
3 is not a determination of non-carcinogenicity or overall safety. It often means that the agent has 
unknown carcinogenic potential and that there are prominent gaps in research. 
The option of merging Groups 2A and 2B was also considered, to address the concern 
expressed by some stakeholders that these groups did not appear to be well distinguished. 
However, because Group 2A and Group 2B are based on distinctly different levels of strength of 
evidence, combining the groups would reduce the utility of the past and future evaluations. 
Recognizing the concern raised, the revised Preamble was enhanced with respect to the clarity 
and transparency for distinguishing between Groups 2A and 2B, particularly with respect to how 
they differ in their indication of strength of evidence. 
While these modifications will clarify the bases of future evaluations, past evaluations 
will remain in effect. For example, Group 2A evaluations that are based solely on limited 
evidence of carcinogenicity in humans according to the 2006 Preamble will not change. Agents 
may be re-evaluated under the most recent Preamble when important additional scientific 
evidence becomes available.  
 
Conclusion 
Overall, the revised Preamble will enable IARC to leverage recent scientific and procedural 
advancements in carcinogenesis and systematic review methodology. The Advisory Group 










epidemiological studies, including their exposure assessment methods, as well as strengthening of 
the systematic review methodology. These developments, in turn, were taken forward in their 
recommendations to clarify and strengthen the process for integrating the three streams of 
evidence – human cancer studies, studies of cancer in experimental animals, and mechanistic 
studies and data – in order to reach an overall evaluation of carcinogenic hazard.  
Looking to the future, implementing the updates in the revised Preamble will allow IARC 
to transparently and consistently apply important advancements in carcinogen hazard 
identification pioneered in the Monographs Programme, with the ultimate aim of more 
effectively serving the public health goal of cancer prevention. 
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Cancer in humans Cancer in experimental animals Mechanistic evidence 
Sufficient (or Strong for 
mechanistic evidence) 
A causal association has been 
established: a positive association 
has been observed in the body of 
evidence on exposure to the agent 
and cancer in studies in which 
chance, bias, and confounding were 
ruled out with reasonable 
confidence. 
A causal relationship has been established 
between exposure to the agent and cancer in 
experimental animals based on an increased 
incidence of malignant neoplasms or of an 
appropriate combination of benign and 
malignant neoplasms in (a) two or more 
species of animals or (b) two or more 
independent studies in one species carried out 
at different times or in different laboratories 
and/or under different protocols or (c) in both 
sexes of a single species in a well-conducted 
study. 
Results in several different experimental 
systems are consistent, and the overall 
mechanistic database is coherent. Further 
support can be provided by studies that 
demonstrate experimentally that the 
suppression of key mechanistic processes 
leads to the suppression of tumour 
development. Typically, a substantial number 
of studies on a range of relevant end-points 
are available in one or more mammalian 
species*  
Limited A causal interpretation of the 
positive association observed in the 
body of evidence on exposure to the 
agent and cancer is credible, but 
chance, bias, or confounding could 
not be ruled out with reasonable 
confidence. 
The data suggest a carcinogenic effect but are 
limited for making a definitive evaluation 
because, for example, (a) evidence of 
carcinogenicity is restricted to a single 
experiment; (b) the agent increases the 
incidence only of benign neoplasms or lesions 
of uncertain neoplastic potential; (c) the agent 
increases tumour multiplicity or decreases 
tumour latency but does not increase tumour 
incidence; (d) the evidence of carcinogenicity 
is restricted to initiation–promotion studies. 
The evidence is suggestive, but, for example, 
(a) the studies cover a narrow range of 
experiments, relevant end-points, and/or 
species; (b) there are unexplained 
inconsistencies in studies of similar design; 
and/or (c) there is unexplained incoherence 
across studies of different end-points or in 
different experimental systems. 
Inadequate No data are available, or the 
available studies are of insufficient 
quality, consistency, or statistical 
precision to permit a conclusion to 
be drawn about the presence or the 
absence of a causal association 
between exposure and cancer. 
The studies cannot be interpreted as showing 
either the presence or the absence of a 
carcinogenic effect because of major 
qualitative or quantitative limitations, or no 
data are available on cancer in experimental 
animals. 
Few or no data are available; there are 
unresolved questions about the adequacy of 
the design, conduct, or interpretation of the 
studies; and/or the available results are 
negative. 
*Quantitative structure–activity considerations, in vitro tests in non-human mammalian cells, and experiments in non-mammalian species may 
provide corroborating evidence but typically do not in themselves provide strong evidence. However, consistent findings across a number of 










Table 2. Integration of streams of evidence in reaching overall classifications 
Stream of evidence 










Sufficient Strong:  
Key characteristics of carcinogens, 
from exposed humans 
Cancer in experimental animals 
and mechanistic evidence 
Limited Sufficient Not necessary Cancer in humans and cancer in 
experimental animals 
Probably carcinogenic to 
humans (Group 2A) 
Inadequate Sufficient Strong:  
Key characteristics of carcinogens, 
from human cells or tissues 
Cancer in experimental animals 
and mechanistic evidence 
Limited Less than Sufficient Strong:  
Key characteristics of carcinogens 




Not necessary Strong:  
The agent belongs to a mechanistic 
class of agents for which one or 
more members have been classified 
in Group 2A or 1 
Mechanistic evidence 
Limited Less than Sufficient Limited or Inadequate Cancer in humans Possibly carcinogenic to 
humans (Group 2B) 
Inadequate Sufficient Not necessary Cancer in experimental animals  
Inadequate Less than Sufficient Strong:  
Key characteristics of carcinogens 
Mechanistic evidence 
Limited Sufficient Strong:  
The mechanism of carcinogenicity 
in experimental animals does not 
operate in humans† 











Inadequate Sufficient Strong:  
The mechanism of carcinogenicity 
in experimental animals does not 
operate in humans† 
Mechanistic evidence Not classifiable as to its 
carcinogenicity to humans 
(Group 3) 
All other situations not listed above  
 
* Highest strength of evidence for any cancer site(s)  
† The “strong evidence that the mechanism of carcinogenicity in experimental animals does not operate in humans” must specifically be for the 











Box 1. The key characteristics of carcinogens described by Smith et al. (2016)27 
 
Ten key characteristics of carcinogens 
1. Is electrophilic or can be metabolically activated to an electrophile 
2. Is genotoxic 
3. Alters DNA repair or causes genomic instability 
4. Induces epigenetic alterations 
5. Induces oxidative stress 
6. Induces chronic inflammation 
7. Is immunosuppressive 
8. Modulates receptor-mediated effects 
9. Causes immortalization 












Box 2. Overall evaluations of the IARC Monographs 
The agent is carcinogenic to humans (Group 1): This category is used whenever there is 
sufficient evidence of carcinogenicity in humans. In addition, this category may apply when 
there is both strong evidence in exposed humans that the agent exhibits key characteristics of 
carcinogens and sufficient evidence of carcinogenicity in experimental animals. 
The agent is probably carcinogenic to humans (Group 2A): This category generally applies 
when the Working Group has made at least two of the following evaluations, including at 
least one that involves either exposed humans or human cells or tissues: 
• Limited evidence of carcinogenicity in humans, 
• Sufficient evidence of carcinogenicity in experimental animals, 
• Strong evidence that the agent exhibits key characteristics of carcinogens. 
Separately, this category generally applies if there is strong evidence that the agent 
belongs, based on mechanistic considerations, to a class of agents for which one or more 
members have been classified in Group 1 or Group 2A. 
The agent is possibly carcinogenic to humans (Group 2B): This category generally applies 
when only one of the following evaluations has been made by the Working Group: 
• Limited evidence of carcinogenicity in humans, 
• Sufficient evidence of carcinogenicity in experimental animals, 
• Strong evidence that the agent exhibits key characteristics of carcinogens (regardless 
of whether from exposed humans or human cells, or from experimental systems). 
The agent is not classifiable as to its carcinogenicity to humans (Group 3): Agents that do 
not fall into any other group are generally placed in this category. Typically, this category is 
used when there is less than sufficient evidence in animals and inadequate evidence in 
humans. This category is also used when there is strong evidence that the mechanism of 
carcinogenicity in experimental animals does not operate in humans and the evidence in 
humans is inadequate. However, if other tumour sites in experimental animals support an 
evaluation of sufficient evidence in experimental animals, or if the evidence in humans is 
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